Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

被引：0
|
作者：
Haruyasu Murakami
Toshihiko Doi
Nobuyuki Yamamoto
Junichiro Watanabe
Narikazu Boku
Nozomu Fuse
Takayuki Yoshino
Atsushi Ohtsu
Satoru Otani
Kazuhiro Shibayama
Takatoshi Takubo
Elwyn Loh
机构：
[1] Shizuoka Cancer Center 1007 Shimonagakubo,
[2] National Cancer Center Hospital East,undefined
[3] St. Marianna University School of Medicine Hospital,undefined
[4] Takeda Bio Development Center Ltd.,undefined
[5] Amgen Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词：
Clinical trial, phase 1; Ganitumab; Gemcitabine; Insulin-like growth factor receptor type 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：407 / 414
页数：7
相关论文
共 50 条
  • [1] Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
    Murakami, Haruyasu
    Doi, Toshihiko
    Yamamoto, Nobuyuki
    Watanabe, Junichiro
    Boku, Narikazu
    Fuse, Nozomu
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Otani, Satoru
    Shibayama, Kazuhiro
    Takubo, Takatoshi
    Loh, Elwyn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 407 - 414
  • [2] Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors
    Doi, T.
    Fuse, N.
    Yoshino, T.
    Murakami, H.
    Yamamoto, N.
    Boku, N.
    Otani, S.
    Shibayama, K.
    Takubo, T.
    Elwyn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
    Tolcher, A. W.
    Rothenberg, M. L.
    Rodon, J.
    Delbeke, D.
    Patnaik, A.
    Nguyen, L.
    Young, F.
    Hwang, Y.
    Haqq, C.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
    Tolcher, Anthony W.
    Sarantopoulos, John
    Patnaik, Amita
    Papadopoulos, Kyriakos
    Lin, Chia-Chi
    Rodon, Jordi
    Murphy, Barbara
    Roth, Bruce
    McCaffery, Ian
    Gorski, Kevin S.
    Kaiser, Brianne
    Zhu, Min
    Deng, Hongjie
    Friberg, Greg
    Puzanov, Igor
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5800 - 5807
  • [5] A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G)
    Sarantopoulos, J.
    Mita, A. C.
    Mulay, M.
    Romero, O.
    Lu, J.
    Capilla, F.
    Chen, L.
    Hwang, Y.
    Friberg, G.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors
    Gore, Lia
    Aisner, Joseph
    Kurzrock, Razelle
    McCarthy, Cinara D.
    Winter, Erica
    Grippe, Joseph
    Frankel, Stanley
    Mita, Alain
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [7] Analysis of biomarkers during early phase clinical development of AMG 479, an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor receptor (IGF-1R)
    McCaffery, I.
    Tolcher, A.
    Puzanov, I.
    Sarantopoulos, J.
    Rosen, L.
    Deng, H.
    Paweletz, K.
    Friberg, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule
    Hidalgo, M.
    Gomez, M. Tirado
    Lewis, N.
    Vuky, J. L.
    Taylor, G.
    Hayburn, J. L.
    Hsu, K.
    Kosh, M.
    Picozzi, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer
    Ray-Coquard, Isabelle
    Haluska, Paul
    O'Reilly, Seamus
    Cottu, Paul H.
    Elit, Lorraine
    Provencher, Diane M.
    Beckmann, Matthias W.
    Bosserman, Linda D.
    Jacod, Sylvie
    Houe, Vincent
    Loberg, Robert D.
    Glaspy, John A.
    Karlan, Beth
    Slamon, Dennis J.
    Konecny, Gottfried E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
    Macaulay, V. M.
    Middleton, M. R.
    Protheroe, A. S.
    Tolcher, A.
    Dieras, V.
    Sessa, C.
    Bahleda, R.
    Blay, J. -Y.
    LoRusso, P.
    Mery-Mignard, D.
    Soria, J. -C.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 784 - 791
12345